International Stem Cell Corporation

http://www.globenewswire.com//International-Stem-Cell-Corp

DID YOU KNOW: One of the most important supplements that Americans don’t get enough of is an Omega-3.

CARLSBAD, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the Company plans to launch its advanced joint supplement, designed to potentially reduce joint pain associated with osteoarthritis, in Q3 2018. The initial launch will be gea...red towards existing Lifeline Skin Care customers, who represent the target demographic and who have been loyal to the brand. The Company will evaluate the results of the soft launch and determine which additional sales channels (i.e. retail, doctors’ offices) it plans to pursue outside of the online space. "The research our scientific team recently published in the Journal of Tissue Engineering and Regenerative Medicine has illustrated that by combining the right ingredients, mesenchymal stem cells possess the remarkable potential to repair human cartilage tissue," commented Russell Kern, PhD, ISCO's Executive Vice President and Chief Scientific Officer. Our scientists have developed a scalable, unique joint supplement designed to potentially reduce joint wear-and-tear, alleviate muscle cramps, and relieve stressed tendons, he continued. According to the Centers for Disease Control and Prevention, osteoarthritis is the most common form of the degenerative joint disease and affects roughly 630 million people worldwide. With this, Technavio analysts are predicting that the global bone and joint supplements market will reach $3.3 billion by the end of 2023. International Stem Cell Corporation Dr. Russell Kern EVP, Chief Scientific Officer (760) 940-6383 [email protected]

International Stem Cell Corporation is Valued at $34 Million Market Value by Edison Investment Research CARLSBAD, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it has been valued at $34 million, up from $33 million in January 2018, by Edison Investment Research ("Edison")*, a world-renowned investment intelligence firm with more than one hundred analysts, investment experts, and roadshow professionals, with offices in North America, Europe, the Middle East and Asia.

Osteoarthritis -- the most common form of arthritis -- currently affects roughly 27 million Americans. Learn more:

Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease and affects approximately one million people in the United States. #themoreyouknow #ParkinsonsAwarenessMonth

Tomorrow marks the birthday of Dr. J Parkinson. On April 11th, there are efforts made to increase public awareness surrounding the disease, as well as all the good works put forth by organizations worldwide dedicated to eradicating it for good.